SERPINA4 and metabolic dysfunction-associated steatotic liver disease: Mechanistically, kallistatin overexpression induced hepatic steatosis and NAFLD in animal models by inhibiting comparative gene identification-58 (CGI-58) and lipotriglyceride lipase (ATGL) via the LRP6/Gαs/PKA/GSK3β pathway.